CIMT

Medigene to Present at Upcoming Conferences

Retrieved on: 
Tuesday, May 7, 2024
Poster, CIMT, Annual general meeting, Conference

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the 21th Association for Cancer Immunotherapy (CIMT) Annual Meeting taking place May 15-17, 2024, in Mainz, as well as at the Healthcare House Call Virtual Conference hosted by The Benchmark Company on May 21 and 22, 2024.

Key Points: 
  • Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the 21th Association for Cancer Immunotherapy (CIMT) Annual Meeting taking place May 15-17, 2024, in Mainz, as well as at the Healthcare House Call Virtual Conference hosted by The Benchmark Company on May 21 and 22, 2024.
  • Further in vitro data will showcase beneficial effects when armoring 3S TCRs with the Company’s PD1-41BB costimulatory switch protein.
  • The poster will be available on Medigene´s website following the conference: https://medigene.com/science/abstracts/
    Members of Medigene’s management team will join a fireside chat and will be available for virtual meetings with registered investors.
  • Please contact Dr. Fotini Vogiatzi at [email protected] to schedule a meeting at the conference.

Compugen Reports First Quarter 2023 Results

Retrieved on: 
Monday, May 15, 2023
Interleukin, Therapy, CRC, Telephone, MSS, Platinum, Cancer, Toxicity, Compugen, Immunotherapy, Patient, Colorectal cancer, TASE, Immune system, TIGIT, PD-1, Ovarian cancer, IND, CIMT, Vaccine, Pharmaceutical industry, PVRIG

R&D expenses for the first quarter of 2023, were approximately $7.4 million compared with approximately $7.2 million for the comparable period in 2022.

Key Points: 
  • R&D expenses for the first quarter of 2023, were approximately $7.4 million compared with approximately $7.2 million for the comparable period in 2022.
  • General and administrative expenses for the first quarter of 2023, were approximately $2.6 million, compared with approximately $2.6 million for the comparable period in 2022.
  • Net loss for the first quarter of 2023, was approximately $9.3 million, or $0.11 per basic and diluted share, compared with a net loss of approximately $9.7 million, or $0.11 per basic and diluted share, in the first quarter of 2022.
  • The Company will hold a conference call today, May 15, 2023, at 8:30 AM ET to review its first quarter 2023 results.

POM v. FTC: A dozen quotable quotes from the D.C. Circuit opinion

Retrieved on: 
Sunday, May 14, 2023
People, Advertising, Section 5, Federal Trade Commission Act of 1914, Awareness, Isabella Tree, Federal Trade Commission, Commission, Suggestion, Policy, Eye, RCT, Constitutional right, Record, Research, Blog, Privacy, Science, First, Butter, Synthetic control method, GAQ, Patient, Time, United States Court of Appeals for the Ninth Circuit, FTC, Risk, Comment, Court, COO, Cardiology, Fraud, POM, Pfizer, D.C, Disease, CIMT, Dietary supplement, Pharmaceutical industry, DRS

POM v. FTC: A dozen quotable quotes from the D.C. Circuit opinionThat’s the conclusion of the United States Court of Appeals in upholding the FTC’s ruling.

Key Points: 

POM v. FTC: A dozen quotable quotes from the D.C. Circuit opinion

    • That’s the conclusion of the United States Court of Appeals in upholding the FTC’s ruling.
    • We think it’s a momentous victory for our two clients: American consumers and the cause of truth in the marketplace.
    • You’ll want to read the entire opinion, of course, but here are twelve quotes from the D.C. Circuit’s decision that businesses, attorneys, and law enforcers will be citing for years to come.
    • As the Court held, “With respect to POM’s establishment claims, the substantiation standard applied by the Commission is consistent with Commission precedent.
    • People can interpret ads more than one way and advertisers must substantiate all reasonable interpretations consumers take from their ads.
    • The company said that it mentioned medical research just to explain the context so consumers could evaluate things for themselves.
    • The opinion carefully evaluated POM’s purported evidence and why the FTC was correct in concluding that it fell short.

Expitope 3.0 presented at CIMT enables more comprehensive analysis of target antigens and increases accuracy of safety assessment

Retrieved on: 
Thursday, May 4, 2023
Faculty, Database, Antigen, Enhanced, HLA, Proteome, FSE, Toxicity, Research, Technical University of Braunschweig, TCR, Protein, Patient, Machine learning, Technical University of Munich, Epitope, Artificial intelligence, Poster, Safety, Phla–Pherá languages, Genome, CIMT, Vaccine

Through this joint endeavor, deep academic expertise in sophisticated bioinformatics, is applied for in silico assessment of potential target antigens for T cell receptor engineered T cell (TCR-T) therapies  for treatment of solid cancer.

Key Points: 
  • Through this joint endeavor, deep academic expertise in sophisticated bioinformatics, is applied for in silico assessment of potential target antigens for T cell receptor engineered T cell (TCR-T) therapies  for treatment of solid cancer.
  • Comparing pHLA epitope expression in various healthy tissues allows to predict potential cross-reactivity and off-target toxicity thereby minimizing safety risks.
  • In summary, Expitope 3.0 allows for a quicker analysis with a broader search of databases and higher prediction accuracy of pHLA epitopes in antigens.
  • We are pleased that this long standing collaboration allowed this updated webtool to be developed to better meet these needs.”

Medigene AG to Present Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)

Retrieved on: 
Thursday, April 27, 2023
TCR, Epitope, Poster, FSE, Toxicity, CIMT, Vaccine

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 20th Association for Cancer Immunotherapy (CIMT) annual meeting being held on May 3-5, 2023, in Mainz.

Key Points: 
  • Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 20th Association for Cancer Immunotherapy (CIMT) annual meeting being held on May 3-5, 2023, in Mainz.
  • The data to be presented will focus on Expitope 3.0, an in silico tool to identify immunogenic epitopes as suitable T cell receptor (TCR) target specificities.
  • Moreover, Expitope 3.0 enables the comparison of expression of epitopes in various healthy tissues to predict potential cross-reactivity and off-target toxicity.
  • The abstract has been published online: https://assets.website-files.com/614b2b26cfb8c9606f742911/64490523a12922...
    Details on the poster presentation are as follows:
    Details on the oral presentation are as follows:

ISA Pharmaceuticals to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual Meeting

Retrieved on: 
Thursday, April 27, 2023
Vaccine, Infection, SLP, Leiden University Medical Center, SARS-CoV-2, B.V, Immunotherapy, Person, Patient, Immune system, Cancer, ISA, Mouse, Immunodeficiency, Therapy, LUMC, CHDR, CIMT

ISA106, a SARS-CoV-2 immunotherapeutic, consists of multiple SLPs derived from the S, N and M proteins, carefully designed for optimal immunogenicity, administration and manufacturability.

Key Points: 
  • ISA106, a SARS-CoV-2 immunotherapeutic, consists of multiple SLPs derived from the S, N and M proteins, carefully designed for optimal immunogenicity, administration and manufacturability.
  • These are demonstrable ex vivo in peripheral blood mononuclear cells (PBMCs) from convalescent donors who recovered from SARS-CoV-2 infection.
  • The data support further development of ISA106 for the protection of immunocompromised people for whom currently approved SARS-CoV-2 vaccines are insufficiently protective."
  • If you would like to meet with ISA Pharmaceuticals at the above event, please contact us at [email protected] .

ISA Pharmaceuticals to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual Meeting

Retrieved on: 
Thursday, April 27, 2023
Vaccine, Infection, SLP, Leiden University Medical Center, SARS-CoV-2, B.V, Immunotherapy, Person, Patient, Immune system, Cancer, ISA, Mouse, Immunodeficiency, Therapy, LUMC, CHDR, CIMT

ISA106, a SARS-CoV-2 immunotherapeutic, consists of multiple SLPs derived from the S, N and M proteins, carefully designed for optimal immunogenicity, administration and manufacturability.

Key Points: 
  • ISA106, a SARS-CoV-2 immunotherapeutic, consists of multiple SLPs derived from the S, N and M proteins, carefully designed for optimal immunogenicity, administration and manufacturability.
  • These are demonstrable ex vivo in peripheral blood mononuclear cells (PBMCs) from convalescent donors who recovered from SARS-CoV-2 infection.
  • The data support further development of ISA106 for the protection of immunocompromised people for whom currently approved SARS-CoV-2 vaccines are insufficiently protective."
  • If you would like to meet with ISA Pharmaceuticals at the above event, please contact us at [email protected] .

Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023
Drug discovery, Cancer, Immunity, NK, Compugen, Immunotherapy, TASE, TME, Poster, Cytokine, Research, Tumor microenvironment, CIMT, Vaccine

HOLON, Israel, April 26, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE:CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present pre-clinical data on its lead pre-clinical asset COM503 in an oral presentation at the 20th CIMT annual meeting, Europe's Cancer Immunotherapy Meeting, on May 3-5, 2023, in Mainz, Germany.

Key Points: 
  • HOLON, Israel, April 26, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE:CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present pre-clinical data on its lead pre-clinical asset COM503 in an oral presentation at the 20th CIMT annual meeting, Europe's Cancer Immunotherapy Meeting, on May 3-5, 2023, in Mainz, Germany.
  • "We are very excited to be presenting our pre-clinical data on COM503, a novel approach to harness cytokine biology to treat cancer, discovered using our proprietary computational discovery platform," said Eran Ophir, Ph.D., SVP Research and Drug Discovery at Compugen.
  • During our oral presentation at CIMT we will present pre-clinical data showing that COM503 binds with high affinity to IL-18 binding protein, freeing IL-18 and restoring NK and T cell activity.
  • The poster and presentation will be made available on the publication section of Compugen's website at www.cgen.com following presentation.

Ancora Training Selected to Lead PepsiCo's Commercial Drivers License and Maintenance Tech Training Programs

Retrieved on: 
Thursday, March 30, 2023
Ancora, Workforce, CDL, Maintenance, Partnership, Driver's licenses in the United States, PepsiCo, CIMT, Heavy equipment, Pepsi

ARLINGTON, Texas, March 30, 2023 /PRNewswire/ -- Ancora Training has been selected by PepsiCo, Inc. to implement and manage two of the global consumer food and beverage corporation's employee upskilling training programs. Ancora will be providing Commercial Drivers License (CDL) training and a Commercial Industrial Maintenance Technician (CIMT) course. Ancora will train Pepsi employees throughout the country as part of the new partnership.

Key Points: 
  • ARLINGTON, Texas, March 30, 2023 /PRNewswire/ -- Ancora Training has been selected by PepsiCo, Inc. to implement and manage two of the global consumer food and beverage corporation's employee upskilling training programs.
  • Ancora will be providing Commercial Drivers License (CDL) training and a Commercial Industrial Maintenance Technician (CIMT) course.
  • As operator of the largest independently owned fleet of trucks in the U.S. , PepsiCo employs more than 25,000 drivers , many of whom require training.
  • Ancora instructors train employees to inspect and operate tractor-trailers and to assume driver responsibilities on the road with emphasis placed on:

BioNTech Presents Encouraging Phase 1/2 Follow-up Data for CAR-T Candidate BNT211 in Hard-To-Treat Solid Tumors at ESMO

Retrieved on: 
Friday, September 9, 2022
European Medicines Agency, European Society for Medical Oncology, Neoplasm, EMA, AACR, Regeneron Pharmaceuticals, Technology, RNA, Safety, American Association for Cancer Research, Cancer, Endometrial cancer, Program, American Association, Fallopian tube cancer, Stomach, CRS, Geneve L. A. Shaffer, CAR, BioNTech, Toxic shock syndrome, Infection, Hoffmann-La Roche, ESMO, SEC, Review, CIMT, PRIME, Testicular cancer, Urna, ORR, Nasdaq, Company, Immunotherapy, Form, Oncology, Association, Congress, RNA transfection, BNTX, Ovarian cancer, Private Securities Litigation Reform Act, Data, Sarcoma, CLDN6, Patient, DCR, Nature, Pharmaceutical industry, Vaccine, Pfizer, Genentech

The results demonstrated encouraging signs of anti-tumor activity and the safety profile remained manageable for the two tested dose levels.

Key Points: 
  • The results demonstrated encouraging signs of anti-tumor activity and the safety profile remained manageable for the two tested dose levels.
  • The product candidate recently received Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) for the third- or later-line treatment of testicular germ cell tumors.
  • The designation was granted based on the encouraging initial data particularly in patients with testicular cancer which is the most common type of germ cell tumors.
  • This new dataset further supports the encouraging results we have seen for BNT211 to date.